Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Significant Increase in Short Interest

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 533,000 shares, a growth of 10.1% from the March 15th total of 484,000 shares. Based on an average daily volume of 661,100 shares, the short-interest ratio is currently 0.8 days. Approximately 4.4% of the shares of the company are sold short.

Acrivon Therapeutics Price Performance

Shares of ACRV opened at $9.61 on Tuesday. Acrivon Therapeutics has a 1 year low of $3.19 and a 1 year high of $14.30. The company has a 50 day simple moving average of $5.60 and a two-hundred day simple moving average of $5.24. The firm has a market cap of $217.57 million, a P/E ratio of -3.52 and a beta of 1.93.

Insider Transactions at Acrivon Therapeutics

In other Acrivon Therapeutics news, major shareholder Perceptive Advisors Llc acquired 2,353,000 shares of the stock in a transaction dated Thursday, April 11th. The shares were purchased at an average price of $8.50 per share, for a total transaction of $20,000,500.00. Following the purchase, the insider now directly owns 5,360,858 shares of the company’s stock, valued at $45,567,293. The acquisition was disclosed in a filing with the SEC, which is available at this link. Company insiders own 7.30% of the company’s stock.

Institutional Investors Weigh In On Acrivon Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund bought a new position in shares of Acrivon Therapeutics during the 1st quarter valued at approximately $28,000. Citigroup Inc. boosted its position in shares of Acrivon Therapeutics by 1,281.2% during the 2nd quarter. Citigroup Inc. now owns 2,790 shares of the company’s stock valued at $36,000 after acquiring an additional 2,588 shares during the last quarter. California State Teachers Retirement System bought a new position in shares of Acrivon Therapeutics during the 1st quarter valued at approximately $41,000. Wells Fargo & Company MN boosted its position in shares of Acrivon Therapeutics by 108.1% during the 2nd quarter. Wells Fargo & Company MN now owns 3,305 shares of the company’s stock valued at $43,000 after acquiring an additional 1,717 shares during the last quarter. Finally, Barclays PLC bought a new position in shares of Acrivon Therapeutics during the 4th quarter valued at approximately $47,000. 71.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ACRV shares. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Acrivon Therapeutics in a report on Thursday, March 28th. JMP Securities reissued a “market outperform” rating and issued a $14.00 target price on shares of Acrivon Therapeutics in a report on Monday, April 1st. LADENBURG THALM/SH SH reduced their target price on shares of Acrivon Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a report on Friday, April 5th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $18.00 target price on shares of Acrivon Therapeutics in a report on Monday, April 1st. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $20.14.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.